Skip to content

Clinical study on the effect of rTMS treatment on the immunoregulatory function of CD4+ T lymphocytes and the expression of phosphorylated a-synuclein in peripheral blood of Parkinson's disease

Clinical study on the effect of rTMS treatment on the immunoregulatory function of CD4+ T lymphocytes and the expression of phosphorylated a-synuclein in peripheral blood of Parkinson's disease

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051140
Enrollment
Unknown
Registered
2021-09-14
Start date
2021-09-15
Completion date
Unknown
Last updated
2022-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease (PD)

Interventions

Group 1:rTMS treatment
Group 2:rTMS sham treatment

Sponsors

Zhujiang Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years, no gender limit; 2. According to the standard diagnosis of the brain bank of the British Parkinson's Disease Society, diagnosed as an idiopathic PD patient; 3. Stable dose of anti-Parkinson's disease drug treatment for >= 28 days, and maintain the dose of treatment during the treatment period; 4. The patient or the guardian of patient voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Secondary Parkinson's syndrome or Parkinson's superimposed syndrome caused by vascular factors, toxins, drugs, etc.; 2. PD patients with persistent head tremor; 3. Previously received DBS or mutilation; 4. Other contraindications for the use of repeated transcranial magnetic stimulation (such as history of epileptic seizures, pregnant women, installation of cardiac pacemakers, metal implants in the body, intracranial hypertension, severe bleeding tendency, etc.); 5. Those who received rTMS treatment in the past 6 months; 6. After evaluation by the investigator, there are other factors that are not suitable for participating in the study or those who cannot insist on completing the follow-up.

Design outcomes

Primary

MeasureTime frame
Treg cells;

Countries

China

Contacts

Public ContactWang Qing

Zhujiang Hospital, Southern Medical University

wqdennis@126.com+86 13829734526

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026